Login to Your Account

CUPID2 misses mark

On the heels of a handful of successful gene therapy IPOs and big pharma investments, analysts and investors were looking for the much-anticipated data from Celladon Corp.'s phase IIb CUPID2 trial testing heart failure candidate Mydicar to be a big win for the space. more »


Partners in Focus